Trial Profile
An Open-Label Prospective, Non-Comparative Study to Evaluate the Subjective Experiences Upon Transition to Paliperidone Extended Release(ER) in Subjects With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2014
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PASS
- Sponsors Janssen
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2012 Actual patient number changed from 27 to 388 as reported by ClinicalTrials.gov.
- 01 Apr 2011 Planned End Date changed from 1 Sep 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.